Hofseth Biocare ASA: Notice of an extraordinary general meeting
December 14, 2023 07:28 ET
|
Hofseth Biocare ASA
Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 13 December regarding an investment of NOK 144 million from Hofseth International AS...
Hofseth Biocare ASA: SIGNIFICANT NEW INVESTMENT OF NOK 144 MILLION FROM HOFSETH INTERNATIONAL INTO HBC
December 13, 2023 16:49 ET
|
Hofseth Biocare ASA
The board of directors (the “Board”) of Hofseth BioCare ASA ("HBC" or the "Company") has reached an agreement with Hofseth International AS (“Hofseth International”) whereby HBC will issue a new class...
Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
November 27, 2023 05:06 ET
|
Hofseth Biocare ASA
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Reference is made to the mandatory notification of trade by Hofseth...
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
November 27, 2023 04:56 ET
|
Hofseth Biocare ASA
Hofseth International AS, a close associate of Board member Roger Hofseth, has today agreed to acquire 435,207 shares in Hofseth BioCare ASA (the "Company"). The shares are purchased at a price of NOK...
Hofseth Biocare ASA: THIRD QUARTER 2023 FINANCIAL REPORT
November 10, 2023 02:00 ET
|
Hofseth Biocare ASA
The third quarter of 2023 shows a significant growth of forty percent in sales compared to the same period last year and the increase in margins in Q2 continues. Sales revenues ended at NOK 49.9m vs...
Hofseth Biocare ASA: SECOND QUARTER 2023 FINANCIAL REPORT
August 25, 2023 02:00 ET
|
Hofseth Biocare ASA
The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and strong increase in margins. Sales revenues ended at NOK 52.9m vs NOK 25.8m last year. The underlying...
Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY
August 17, 2023 02:58 ET
|
Hofseth Biocare ASA
HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required minimum seed capital financing of approx. USD 900,000...
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
July 14, 2023 08:33 ET
|
Hofseth Biocare ASA
Christel Elise Kanli, primary insider and CFO/COO in Hofseth BioCare ASA («HBC») has today purchased 74,000 shares in HBC at an average price of approx. NOK 2.70 per share. As a result of the...
Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
May 30, 2023 02:40 ET
|
Hofseth Biocare ASA
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer...
Hofseth Biocare ASA: SPIN-OFF OF PROSTATE CANCER CO-TREATMENT PROJECT
May 15, 2023 01:50 ET
|
Hofseth Biocare ASA
Hofseth Biocare ASA ("HBC" or the "Company") today announces the decision to transfer its prostate cancer co-treatment project (the "Project") to a new US entity to be called HBC Immunology Inc....